Overall (n=43) | Small LGE (n=21) | Large LGE (n=22) | p Value | |
---|---|---|---|---|
Small vs large | ||||
Age (years) | 59±10 | 59±12 | 60±9 | 0.798 |
Male, n (%) | 15 (35) | 6 (29) | 9 (41) | 0.396 |
Body Mass Index (kg/m2) | 22.3±3.1 | 22.7±3.0 | 21.9±3.3 | 0.417 |
Systolic blood pressure (mm Hg) | 123±18 | 126±17 | 120±18 | 0.250 |
Diastolic blood pressure (mm Hg) | 72±12 | 71±11 | 73±13 | 0.642 |
NYHA functional class | 0.875 | |||
I, n (%) | 7 (16) | 4 (19) | 3 (14) | |
II, n (%) | 27 (63) | 13 (62) | 14 (64) | |
III, n (%) | 9 (21) | 4 (19) | 5 (23) | |
IV, n (%) | 0 (0) | 0 (0) | 0 (0) | |
Organ involvement | ||||
Lung, n (%) | 9 (21) | 4 (19) | 5 (23) | 0.767 |
Eye, n (%) | 3 (7) | 2 (10) | 1 (5) | 0.522 |
Skin, n (%) | 2 (5) | 1 (5) | 1 (5) | 0.973 |
Laboratory results at the beginning of steroid therapy | ||||
White blood cell count (/μL) | 5701±1587 | 5428±1288 | 5961±1820 | 0.276 |
Haemoglobin (g/dL) | 13.4±1.5 | 13.3±1.6 | 13.4±1.3 | 0.709 |
Serum creatinine (mg/dL) | 0.8±0.2 | 0.8±0.2 | 0.8±0.2 | 0.845 |
eGFR (mL/min/1.73m2) | 55±15 | 54±14 | 56±16 | 0.640 |
Albumin (g/dL) | 4.1±0.3 | 4.0±0.3 | 4.1±0.3 | 0.573 |
Calcium (mg/dL) | 9.5±0.4 | 9.4±0.2 | 9.6±0.6 | 0.311 |
BNP (pg/mL) | 293±233 | 216±174 | 368±261 | 0.031 |
ACE (U/L) | 14.7±8.4 | 15.0±9.2 | 14.4±7.6 | 0.843 |
Lysozyme (μg/mL) | 8.0±4.1 | 7.2±3.2 | 8.9±5.0 | 0.222 |
Medications at the beginning of steroid therapy | ||||
β blockers, n (%) | 18 (42) | 8 (38) | 10 (45) | 0.625 |
ACE inhibitors, n (%) | 17 (40) | 7 (33) | 10 (45) | 0.416 |
ARB, n (%) | 9 (21) | 4 (19) | 5 (23) | 0.767 |
Diuretics, n (%) | 23 (53) | 9 (43) | 14 (64) | 0.172 |
Antiarrhythmic agents, n (%) | 9 (21) | 5 (24) | 4 (18) | 0.650 |
Implanted devices at the beginning of steroid therapy | ||||
Pacemaker, n (%) | 7 (16) | 5 (24) | 2 (9) | 0.191 |
Implantable cardioverter defibrillator, n (%) | 7 (16) | 3 (14) | 4 (18) | 0.729 |
Cardiac resynchronisation therapy, n (%) | 2 (5) | 0 (0) | 2 (9) | 0.157 |
Echocardiographic analysis | ||||
LVEF (%) | 41±10 | 45±11 | 36±6 | 0.001 |
LV diastolic dimension (mm) | 57±8 | 52±6 | 61±8 | <0.001 |
LV systolic dimension (mm) | 44±9 | 39±8 | 49±7 | <0.001 |
LV end-diastolic volume index (mL/m2) | 111±38 | 92±27 | 130±38 | <0.001 |
LV end-systolic volume index (mL/m2) | 68±31 | 52±22 | 84±30 | <0.001 |
CMR analysis | ||||
LVEF (%) | 38±12 | 43±12 | 32±10 | 0.002 |
LV end-diastolic volume index (mL/m2) | 112±42 | 92±27 | 132±45 | 0.001 |
LV end-systolic volume index (mL/m2) | 73±38 | 54±24 | 91±41 | <0.001 |
LV mass (g) | 130±38 | 122±47 | 138±27 | 0.195 |
LV mass index (g/m2) | 82±23 | 78±28 | 87±17 | 0.219 |
LGE mass (g) | 26±16 | 14±11 | 38±11 | <0.001 |
% LGE mass (%) | 19±10 | 11±5 | 28±5 | <0.001 |
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BNP, B-type natriuretic peptide; CMR, cardiovascular magnetic resonance; eGFR, estimated glomerular filtration rate; LGE, late gadolinium enhancement; NYHA, New York Heart Association.